Pentostatin, Cyclophosphamide and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E2903)

Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utilizing pentostatin, cyclophosphamide, and rituximab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Haematol
Hlavní autoři: Kempin, Sanford, Sun, Zhuoxin, Kay, Neil E., Paietta, Elisabeth M., Mazza, Joseph J., Ketterling, Rhett P., Frankfurt, Olga, Claxton, David F., Saltzman, Joel N., Srkalovic, Gordan, Callander, Natalie S., Gross, Gerald, Tallman, Martin S
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6834875/
https://ncbi.nlm.nih.gov/pubmed/31336367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000500164
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky